A Four-way Cross-over Multiple-dose Open-label Pharmacokinetic Drug Interaction Study with Esomeprazole 20 mg b.i.d., Metronidazole 500 mg b.i.d., Clarithromycin 250 mg b.i.d., and their combination b.i.d. in Healthy Non-smoking Male and Female Subjects.
Study identifier:SH-NEH-0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Four-way Cross-over Multiple-dose Open-label Pharmacokinetic Drug Interaction Study with Esomeprazole 20 mg b.i.d., Metronidazole 500 mg b.i.d., Clarithromycin 250 mg b.i.d., and their combination b.i.d. in Healthy Non-smoking Male and Female Subjects.
Medical condition
gastrointestinal diseases
Phase
Phase 4
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 2001
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
